Cargando…

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation

OBJECTIVE: Cisplatin is the first‐line chemotherapy for ovarian cancer. However, cisplatin resistance is severely affecting the treatment efficacy. FOXO3a has been reported to be involved in reversing chemotherapy resistance. However, whether low‐dose fraction radiation therapy (LDFRT) can reverse c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lili, Liu, Shihai, Liang, Donghai, Jiang, Tao, Yan, Xiaoyan, Zhao, Shengnan, Liu, Yuanwei, Zhao, Wei, Yu, Hongsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536942/ https://www.ncbi.nlm.nih.gov/pubmed/30941896 http://dx.doi.org/10.1002/cam4.2116

Ejemplares similares

Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells
por: Chun, Jaemoo
Publicado: (2023)

MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
por: Liu, Ruonan, et al.
Publicado: (2018)

BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma
por: Gao, Wei, et al.
Publicado: (2017)

FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3
por: Xiong, Xifeng, et al.
Publicado: (2022)

MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway
por: Lin, Zhilai, et al.
Publicado: (2020)

Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells
por: Uzawa, Katsuhiro, et al.
Publicado: (2013)

Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma
por: Hastings, Jordan F, et al.
Publicado: (2020)

Apoptin‐derived peptide reverses cisplatin resistance in gastric cancer through the PI3K–AKT signaling pathway
por: Zhou, Danyang, et al.
Publicado: (2018)

USP14 as a novel prognostic marker promotes cisplatin resistance via Akt/ERK signaling pathways in gastric cancer
por: Fu, Ying, et al.
Publicado: (2018)

Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2
por: Ke, Bin, et al.
Publicado: (2019)

The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model
por: Wertman, Jaime N, et al.
Publicado: (2020)

Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD‐L1
por: Zhang, Pei, et al.
Publicado: (2018)

Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells
por: Sima, Ni, et al.
Publicado: (2018)

Vitamin D(3) enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk
por: Bunch, Brittany L., et al.
Publicado: (2019)

SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis
por: Cao, Yang, et al.
Publicado: (2021)

Cordycepin Resensitizes T24R2 Cisplatin-Resistant Human Bladder Cancer Cells to Cisplatin by Inactivating Ets-1 Dependent MDR1 Transcription
por: Oh, Sang-Seok, et al.
Publicado: (2020)

Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors
por: Crean-Tate, Katie K., et al.
Publicado: (2021)

IL‐25 promotes cisplatin resistance of lung cancer cells by activating NF‐κB signaling pathway to increase of major vault protein
por: Shen, Weiming, et al.
Publicado: (2019)

Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer
por: Kaltofen, Till, et al.
Publicado: (2020)

Osthole resensitizes CD133(+) hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway
por: Ye, Junfeng, et al.
Publicado: (2020)

HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3
por: Hou, Xuyang, et al.
Publicado: (2020)

Glycan signatures for the identification of cisplatin‐resistant testicular cancer cell lines: Specific glycoprofiling of human chorionic gonadotropin (hCG)
por: Hires, Michal, et al.
Publicado: (2022)

Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway
por: Li, Han, et al.
Publicado: (2019)

Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cisplatin with six fractions per week radiotherapy in locally advanced head neck cancer
por: Gupta, Pramod Kumar, et al.
Publicado: (2016)

Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations
por: Lopez-Ayllon, Blanca D, et al.
Publicado: (2014)

Effects of Pretreatment With Single-Dose or Intermittent Oxygen on Cisplatin-Induced Nephrotoxicity in Rats
por: Rasoulian, Bahram, et al.
Publicado: (2014)

Pretreatment of Huaiqihuang extractum protects against cisplatin-induced nephrotoxicity
por: Guo, Yujiao, et al.
Publicado: (2018)

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
por: Furqan, Muhammad, et al.
Publicado: (2019)

The effect of FASN inhibition on the growth and metabolism of a cisplatin‐resistant ovarian carcinoma model
por: Papaevangelou, Efthymia, et al.
Publicado: (2018)

Long non‐coding RNA H19 promotes TDRG1 expression and cisplatin resistance by sequestering miRNA‐106b‐5p in seminoma
por: Wei, Jingchao, et al.
Publicado: (2018)

Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters
por: Katsui, Kuniaki, et al.
Publicado: (2020)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma
por: Osaki, Akihiko, et al.
Publicado: (2013)

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

The out-of-field dose in radiation therapy induces delayed tumorigenesis by senescence evasion
por: Goy, Erwan, et al.
Publicado: (2022)

Activation of PTGS2/NF‐κB signaling pathway enhances radiation resistance of glioma
por: Tan, Cheng, et al.
Publicado: (2019)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

Deregulation of Exo70 Facilitates Innate and Acquired Cisplatin Resistance in Epithelial Ovarian Cancer by Promoting Cisplatin Efflux
por: Zhao, Yujie, et al.
Publicado: (2021)

Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α
por: Keremu, Ajimu, et al.
Publicado: (2019)

Efficiency of high cumulative cisplatin dose in high‐ and low‐risk patients with locoregionally advanced nasopharyngeal carcinoma
por: Jiang, Yu‐Ting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qckjp0q39t3gt3mevr7tv5br1m